Published in Br J Haematol on March 01, 1976
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS. J Clin Invest (1949) 8.50
Thrombolytic therapy: current status (1). N Engl J Med (1988) 5.44
Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol (1982) 4.08
Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell (1986) 2.85
Retinal arterial obstruction in children and young adults. Ophthalmology (1981) 2.45
THE VITAMIN C REQUIREMENT OF MAN. ESTIMATED AFTER PROLONGED STUDIES OF THE PLASMA CONCENTRATION AND DAILY EXCRETION OF VITAMIN C IN 3 ADULTS ON CONTROLLED DIETS. J Clin Invest (1939) 2.43
A third quaternary structure of human hemoglobin A at 1.7-A resolution. J Biol Chem (1992) 2.32
Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA (1992) 2.27
Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol (1984) 2.13
High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem (1969) 2.09
Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. Br J Haematol (1972) 2.06
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97
NF-kappa B-dependent inhibition of apoptosis is essential for host cellsurvival during Rickettsia rickettsii infection. Proc Natl Acad Sci U S A (1998) 1.92
The interaction of hemoglobin with the cytoplasmic domain of band 3 of the human erythrocyte membrane. J Biol Chem (1984) 1.83
Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem (1983) 1.77
Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest (1985) 1.76
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Interface sliding as illustrated by the multiple quaternary structures of liganded hemoglobin. Biochemistry (2000) 1.61
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol (2012) 1.60
A rapid method for removal of [125I]iodide following iodination of protein solutions. Anal Biochem (1980) 1.56
Metabolism and function of human platelets washed by albumin density gradient separation. Br J Haematol (1977) 1.56
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest (1969) 1.52
Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol (1974) 1.51
Thrombolytic therapy: current status (2). N Engl J Med (1988) 1.49
Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators. Am J Cardiol (2000) 1.47
The relationship between quality of life and self-determination: an international study. J Intellect Disabil Res (2005) 1.47
The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med (1969) 1.45
Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies. Am J Med (1971) 1.41
Enhancement of fibrinolysis in vitro by ultrasound. J Clin Invest (1992) 1.41
Acquired "storage pool disease" of platelets associated with circulating antiplatelet antibodies. Am J Med (1974) 1.40
Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences. AJR Am J Roentgenol (1990) 1.39
Thrombogenic factors and recurrent coronary events. Circulation (1999) 1.38
Unusual anemias. Am J Hematol (1997) 1.38
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest (1969) 1.34
Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood (1981) 1.34
Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol (1986) 1.34
The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta (1986) 1.31
The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry (1966) 1.31
Current status of antithrombotic therapy in cardiovascular disease. Prog Cardiovasc Dis (1977) 1.31
THE MECHANISM OF THE EXCRETION OF VITAMIN C BY THE HUMAN KIDNEY AT LOW AND NORMAL PLASMA LEVELS OF ASCORBIC ACID. J Clin Invest (1940) 1.30
Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (lysine 99 alpha 1----lysine 99 alpha 2). J Biol Chem (1986) 1.30
Comparative activity of thrombin on substituted arginine and lysine esters. Am J Physiol (1965) 1.28
High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J Biol Chem (1969) 1.28
Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome. Am Rev Respir Dis (1985) 1.27
Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci (1965) 1.27
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg (1994) 1.26
Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med (1977) 1.26
von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood (1987) 1.25
Fibrinolysis. Annu Rev Med (1968) 1.20
Refinement and comparisons of the crystal structures of pig cytosolic aspartate aminotransferase and its complex with 2-methylaspartate. J Biol Chem (1997) 1.20
Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity. Blood (1980) 1.18
Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. Ann Intern Med (1986) 1.17
Comparative interactions of factor IX and factor IXa with human platelets. J Biol Chem (1989) 1.17
Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility. Biochemistry (1967) 1.17
Hereditary giant platelet syndrome. Absence of collagen-induced coagulant activity and deficiency of factor-XI binding to platelets. Br J Haematol (1975) 1.16
Retracted Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J Biol Chem (2000) 1.16
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am (1997) 1.16
Crystal structure of the S-nitroso form of liganded human hemoglobin. Biochemistry (1998) 1.14
High-resolution X-ray study of deoxyhemoglobin Rothschild 37 beta Trp----Arg: a mutation that creates an intersubunit chloride-binding site. Biochemistry (1992) 1.14
The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med (1979) 1.14
Acquired qualitative platelet disorders. Clin Haematol (1983) 1.13
Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood (1985) 1.13
Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis. Am Rev Respir Dis (1987) 1.13
Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A (1987) 1.10
Kinetics of coagulation factor X activation by platelet-bound factor IXa. Biochemistry (1990) 1.10
Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis. Thromb Haemost (1985) 1.10
Structural studies of the functional heterogeneity of von Willebrand protein polymers. Blood (1981) 1.10
Interleukin-1 alpha production during Rickettsia rickettsii infection of cultured endothelial cells: potential role in autocrine cell stimulation. Infect Immun (1996) 1.10
Platelet antiheparin activity: storage site and release mechanism. Blood (1974) 1.10
Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments. Proc Natl Acad Sci U S A (1990) 1.09
Rickettsia rickettsii infection of cultured human endothelial cells induces NF-kappaB activation. Infect Immun (1997) 1.09
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. Circulation (1985) 1.08
Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood (1987) 1.08
E-selectin-dependent neutrophil adhesion to Rickettsia rickettsii-infected endothelial cells. Blood (1993) 1.08
Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol (1971) 1.07
Rickettsia rickettsii infection of cultured endothelial cells induces release of large von Willebrand factor multimers from Weibel-Palade bodies. Blood (1991) 1.07
Von Willebrand protein binds to extracellular matrices independently of collagen. Proc Natl Acad Sci U S A (1984) 1.07
Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. J Am Coll Cardiol (1992) 1.07
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J Thromb Haemost (2005) 1.06
Chronic intravascular coagulation syndrome. N Engl J Med (1968) 1.06
The role of platelets in intrinsic factor-Xa formation. Br J Haematol (1972) 1.06
Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. Blood (2001) 1.05
Structure of plasmic degradation products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis. J Biol Chem (1974) 1.05
Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. JAMA (1983) 1.05
Platelet coagulant activities in diabetes mellitus. Evidence for relationship between platelet coagulant hyperactivity and platelet volume. J Lab Clin Med (1984) 1.05
Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost (1994) 1.04
Purification and characterization of a highly purified human factor VIII consisting of a single type of polypeptide chain. Proc Natl Acad Sci U S A (1982) 1.04
Nitrophorin-2: a novel mixed-type reversible specific inhibitor of the intrinsic factor-X activating complex. Biochemistry (1998) 1.03
Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Am Heart J (1992) 1.03
Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction: acute and follow-up studies. Am J Cardiol (1984) 1.03
Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med (1983) 1.02
Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood (1980) 1.02
Ultrasound enhancement of thrombolysis and reperfusion in vitro. J Am Coll Cardiol (1993) 1.01
Platelet coagulant activities and hemostasis: a hypothesis. Blood (1974) 1.01
Identification and chemical synthesis of a substrate-binding site for factor IX on coagulation factor XIa. J Biol Chem (1991) 1.00